MK-677 vs Sermorelin
Both MK-677 and Sermorelin are used for growth-hormone and anti-aging. Here's how their evidence, dosing, and regulatory status actually compare.
MK-677
Evidence B+Ibutamoren (MK-677)
An orally active ghrelin-receptor agonist that drives 24-hour increases in GH and IGF-1. Technically a non-peptide small molecule but always grouped with GH peptides.
View full MK-677 profile →Sermorelin
Evidence B+Sermorelin Acetate (GHRH 1-29)
The original synthetic GHRH(1–29) and the most accessible GH-stimulating peptide for age-related hormone decline. Stimulates the body's own pulsatile GH release rather than replacing it.
View full Sermorelin profile →Side-by-Side
| Attribute | MK-677 | Sermorelin |
|---|---|---|
| Evidence Grade | B+ | B+ |
| FDA Status | Not FDA-approved — investigational (orally active GH secretagogue) | FDA-approved (1990) for pediatric growth hormone deficiency; off-label adult use via compounding pharmacies |
| Typical Dose | 10–25 mg orally, once daily | 200–500 mcg before bed (subcutaneous) |
| Clinics Indexed | 165 | 220 |
| Categories | growth-hormone, anti-aging | growth-hormone, anti-aging |
Key reported benefits — MK-677
- ✓Sustained GH/IGF-1 elevation
- ✓Sleep depth
- ✓Lean mass
- ✓Bone density
Key reported benefits — Sermorelin
- ✓Natural GH release
- ✓Improved sleep
- ✓Lean body mass
- ✓Recovery
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.